In fact, resulting from this research, everolimus is currently the only mTOR inhibitor approved in various countries for the treatment of patients with more than 3 years of age with TSC-related SEGA who are not candidates for curative surgical resection [9] and adults with TSC-associated renal angiomyolipomas who are at risk of complications, but who do not require immediate surgery [10]. The gene discussed is MTOR; the disease is kidney angiomyolipoma.